![Kelley A. Wendt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kelley A. Wendt
Plus aucun poste en cours
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Philip Young | M | 66 | 3 ans | |
Ezra J. Green | M | 61 | 3 ans | |
Elliot M. Maza | M | 68 | 1 ans | |
John Price | M | 54 | 2 ans | |
Emiliano Aloi | M | 50 | 1 ans | |
Timothy Ryan | M | 63 | 3 ans | |
Kenneth E. Puzder | M | 58 | 1 ans | |
Sandra Morales | M | - |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
Andrew L. Johnson | M | 38 | 2 ans | |
Baxter Phillips | M | 48 |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 ans |
Jeffrey Thompson | M | 60 | 1 ans | |
Kevin James Esval | M | 60 | 1 ans | |
Wendy Johnson | F | 72 |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 5 ans |
Nathan Berman | M | 36 | - | |
Anthony P. Gellert | M | - |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
Anthony Smithyman | M | 74 |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 ans |
Krassen Dimitrov | M | - | 1 ans | |
Caroline Ann Williams | M | 70 |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
James R. Erickson | M | 62 | 3 ans | |
Jonathan Gilbert | M | 52 | - | |
Julian P. Kirk | M | 50 |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 21 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Kelley A. Wendt
- Réseau Personnel